Five Innovative TCM Drugs Approved in China in Five Months

In short

Between June and October 2026, China's National Medical Products
Administration (NMPA) approved five Class 1.1 innovative traditional
Chinese medicine drugs — for insomnia, lingering post-infection cough,
knee osteoarthritis pain, childhood constipation, and mild-to-moderate
depression. Several were approved for a TCM syndrome rather than a
Western disease name, a regulatory first. The approvals show TCM
operating as a regulated, evidence-tested pharmaceutical sector — not as
unregulated folk remedy. All five are listed below with their makers and
approved uses.

The five approvals, June–October 2026

[TABLE]

In the same mid-October batch, the NMPA also approved three Class 3.1
compound preparations derived from classic famous formulas
（经典名方） — the other fast-moving lane of TCM regulation, where
officially catalogued classical prescriptions are brought to market as
standardised products.

The regulatory story underneath

China's reformed TCM registration system sorts products by how new they
are. Class 1.1 is the innovation lane: new formulas with claimed
clinical value that must earn approval through the modern pathway,
including clinical evidence review. Class 3.1 is the heritage lane:
preparations of classic famous formulas. Five Class 1.1 approvals in
five months is a harvest pace the sector has not shown before, and the
pattern of the five is telling:

• They start from clinical experience formulas — prescriptions
  refined in hospital practice — then validate them with modern trial
  methods, rather than copying ancient texts wholesale.
• They target unmet niches: warm-natured cough remedies were scarce
  among mostly "cold/cooling" Chinese cough medicines; syndrome-defined
  insomnia and depression had few licensed options.
• Two of the five are syndrome-indicated — approved for a TCM
  pattern, not a biomedical disease — signalling that regulators will
  license on TCM's own diagnostic terms when the evidence is built
  accordingly.

What this means for international patients

• TCM in China is a licensed pharmaceutical system. Herbal products
  prescribed in Chinese hospitals are approved, manufactured and
  labelled under NMPA rules — a different world from imported "herbal
  supplements" sold abroad with no drug approval.
• New options exist in areas patients already seek TCM for — sleep,
  lingering cough, joint pain, mood. They are prescribed after a
  doctor's pattern diagnosis; whether one fits you is a clinical
  decision, not a shopping choice.
• Approval is not proof of superiority. These are brand-new (2026)
  products; long-term real-world data is still accumulating, and
  syndrome-based indications mean fit depends on your individual pattern
  as diagnosed in consultation.

PriumCare does not sell or recommend medicines. What we do is coordinate
care at the hospitals where this medicine is practised — so if you come
to China for TCM treatment, the prescribing decisions are made by
licensed doctors, with your records prepared and follow-up arranged.

Frequently asked questions

What is a Class 1.1 innovative TCM drug in China?

Under China's drug registration system for traditional Chinese medicine,
Class 1.1 covers innovative TCM products — new formulas or preparations
with demonstrated clinical value that must go through the modern
approval pathway, including clinical trials, before the NMPA (National
Medical Products Administration) licenses them. It is the TCM equivalent
of an innovative-drug category, distinct from Class 3.1 products, which
are compound preparations derived from officially catalogued classic
famous formulas （经典名方）.

Which innovative TCM drugs were approved in China in 2026?

Five Class 1.1 approvals landed between June and October 2026: Zaoren
Ningxin Dripping Pills (Tasly) for insomnia, in June; Jiaoqi Zhitong Gel
Patch (Jiudian Pharmaceutical) for knee osteoarthritis, in July; Xiao'er
Tongbian Granules (Jumpcan) for childhood constipation, in August;
Xingpi Jieyu Tablets (Tongjitang) for mild-to-moderate depression, in
September; and Zihua Wenfei Zhisou Granules (Yuekang) for lingering
wind-cold pattern cough, on 16 October. In the same October batch, the
NMPA also approved three Class 3.1 classic-formula compound
preparations.

Why are these drugs approved for "syndromes" instead of diseases?

Several of the 2026 approvals are indicated for a TCM syndrome （证候）
— a diagnosed pattern such as "wind-cold lingering in the lung" — rather
than a Western disease name. Chinese regulators now accept
syndrome-based indications for TCM where the clinical evidence supports
them; the Xiao'er Tongbian Granules approval in August 2026 was the
first syndrome-indicated innovative TCM approved under the dedicated TCM
registration rules. In practice it means a TCM doctor's pattern
diagnosis determines whether the drug fits you.

Can I buy these TCM drugs outside China?

These are prescription medicines approved for the mainland China market;
they are not generally marketed or licensed abroad, and they are
prescribed by doctors in Chinese hospitals after consultation — they are
not supplements sold over the counter. If you are treated in China, your
doctor decides whether any of them is appropriate for your pattern and
condition.

Sources and notes

• National Medical Products Administration (NMPA) approval
  announcements, June–October 2026 — including the 16 October 2026
  approval of Zihua Wenfei Zhisou Granules; roundup and product details
  via Pharmaceutical Network （制药网）, 19 October 2026.
• Yuekang Pharma (688658) regulatory announcement on the Zihua Wenfei
  Zhisou Granules approval, 15 October 2026.
• Approved indications are summarised from the official approval
  descriptions; TCM pattern names are translated descriptively. This
  article is information about regulatory approvals, not a treatment
  recommendation.

PriumCare / 沛瑞医疗 is a medical travel coordination service.
We do not provide medical diagnosis or treatment, and we do not sell
medicines; all prescribing is by licensed doctors at Chinese hospitals.
Information current as of 22 October 2026.

Keep reading

• Beijing's 18 pilot hospitals,
  explained
• Beijing's 40 TCM packages,
  explained
• Boao Lecheng visa guide
• CIHA vs JCI,
  explained
• Healthcare in China for foreigners — the full
  guide